240 - 2025 Case-Based Gu(ID)elines: COVID-19 Treatment and Management, Histoplasmosis and Strep Pharyngitis

Wednesday, October 22, 2025

1:45 PM - 3:00 PM US ET

Location: Thomas B. Murphy Ballroom 2-3

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Ronald Nahass, MD

President
ID Care
Hillsborough, NJ, United States
Sharon Weissman, MD (she/her/hers)

Professor of Medicine
University of South Carolina
Columbia, SC, United States

Faculty(s)

Andrej Spec, M.D., MSCI (he/him/his)

Associate Professor
Infectious Diseases
Washington University School of Medicine in St. Louis
St. Louis, Missouri, United States
MB

Miriam Barshak, MD (she/her/hers)

Associate Professor of Medicine
Harvard Medical School, Massachusetts General Hospital
Boston, MA, United States
Michael Watson, Jr., MD, PhD (he/him/his)

Clinical Associate Professor of Pediatrics
Department of Pediatrics
University of Michigan
Ann Arbor, MI, United States
RG

Rajesh Gandhi, MD (he/him/his)

Professor of Medicine
Harvard Medical School
Boston, MA, United States
Sandra Arnold, MD, MSc (she/her/hers)

Professor of Pediatrics
University of Tennessee Health Science Center
Memphis, TN, United States

Disclosure(s):

Ronald G. Nahass, MD: No financial relationships to disclose.

Sharon Weissman, MD: No financial relationships to disclose.

Andrej Spec, M.D., MSCI: No financial relationships to disclose.

Miriam Barshak, MD: Boston Scientific: Stocks/Bonds (Private Company); Danaher Corporation: Stocks/Bonds (Private Company); UpToDate Wolters Kluwer Health: Royalties (for authorship)

Michael E. Watson, MD, PhD, Jr.: No financial relationships to disclose.

Rajesh Gandhi, MD: No financial relationships to disclose.

Sandra Arnold, MD, MSc: Pfizer, Inc.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

evaluate how treatment recommendations, endorsed by multiple professional societies, contribute to improving patient outcomes in severe COVID-19 management;
discuss the strengths and limitations of using itraconazole as the first-line treatment for mild to moderate acute pulmonary histoplasmosis;
describe the latest recommendations for the treatment of strep pharyngitis.

Presentations:

1:45 PM - 2:10 PM US ET

COVID-19: Treatment and Management
Speaker: Rajesh Gandhi, MD (he/him/his) – Harvard Medical School
2:10 PM - 2:35 PM US ET

Histoplasmosis
Speaker: Sandra Arnold, MD, MSc (she/her/hers) – University of Tennessee Health Science Center
Speaker: Andrej Spec, M.D., MSCI (he/him/his) – Washington University School of Medicine in St. Louis
2:35 PM - 3:00 PM US ET

Update on Guidelines for Management of Group A Streptococcal Pharyngitis
Speaker: Miriam Barshak, MD (she/her/hers) – Harvard Medical School, Massachusetts General Hospital
Speaker: Michael E. Watson, Jr., MD, PhD (he/him/his) – University of Michigan